On May 23, 2006, the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, was launched to examine whether genes that are frequently associated with risk of recurrence for women with early-stage breast cancer can be used to assign patients to the most appropriate and effective treatment.

TAILORx will determine the most effective current approach to cancer treatment, with the fewest side effects, for women with early-stage breast cancer by using Oncotype DX™, a validated diagnostic test developed by Genomic Health, Redwood City, Calif., in collaboration with the National Surgical Adjuvant Breast and Bowel Project (NSABP), a network of cancer research professionals.

TAILORx was the first trial to be launched as part of a new NCI program­­, the Program for the Assessment of Clinical Cancer Tests (PACCT), which seeks to individualize cancer treatment by using, evaluating and improving the latest diagnostic tests. The research appeared in the Journal of Clinical Oncology.